HanaTotary-Jain

Hana Totary-Jain, PhD

Assistant Professor, College Of Medicine Molecular Pharmacology & Physiology

College Of Medicine Molecular Pharmacology & Physiology

Assistant Professor, Molecular Pharmacology and Physiology, University of South Florida

Contact Info 12901 Bruce B. Downs Blvd.
MDC8, Room 2025
Tampa, FL 33612

Academic Email: totaryjainh@health.usf.edu

Academic Phone: (813) 974-6821

View My C.V.

Education

  • PhD, Pharmacology, The Hebrew University Of Jerusalem, 2005

Interdisciplinary and Emerging Signature Programs

  • Cardiovascular
  • Cardiovascular Sciences
  • Cellular and Molecular Biology

Research Interests

  • Our research is focused on elucidating novel mechanisms underlying the roles of non-coding RNA in different vascular diseases. We are currently working on two different areas: 1) use non-coding RNA to confer tissue specificity to novel therapeutics for vascular diseases, including coronary artery stent restenosis. We have developed an innovative approach that exploits endogenous microRNAs to specifically inhibit smooth muscle cell proliferation, the major cause of restenosis, without affecting re-endothelialization. 2) Study the role of microRNA in infantile hemangioma

Recent Publications

  • Santulli, G.Totary-Jain, H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 14(12) : 1517-26, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24024901
  • Totary-Jain, H.Marks, AR. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy. Cell cycle (Georgetown, Tex.). 12(6) : 861-2, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23442794
  • Totary-Jain, H.Sanoudou, D.Ben-Dov, IZ.Dautriche, CN.Guarnieri, P.Marx, SO.Tuschl, T.Marks, AR. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. The Journal of biological chemistry. 288(9) : 6034-44, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23300087
  • Totary-Jain, H.Sanoudou, D.Dautriche, CN.Schneller, H.Zambrana, L.Marks, AR. Rapamycin resistance is linked to defective regulation of Skp2. Cancer research. 72(7) : 1836-43, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22311674
  • Marx, SO.Totary-Jain, H.Marks, AR. Vascular smooth muscle cell proliferation in restenosis. Circulation. Cardiovascular interventions. 4(1) : 104-11, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21325199
  • Shan, J.Nguyen, TB.Totary-Jain, H.Dansky, H.Marx, SO.Marks, AR. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 105(48) : 19006-11, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19020099
  • Totary-Jain, H.Naveh-Many, T.Riahi, Y.Kaiser, N.Eckel, J.Sasson, S. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circulation research. 97(10) : 1001-8, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16210549
  • Alpert, E.Altman, H.Totary, H.Gruzman, A.Barnea, D.Barash, V.Sasson, S. 4-Hydroxy tempol-induced impairment of mitochondrial function and augmentation of glucose transport in vascular endothelial and smooth muscle cells. Biochemical pharmacology. 67(10) : 1985-95, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15130774
  • Alpert, E.Gruzman, A.Totary, H.Kaiser, N.Reich, R.Sasson, S. A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. The Biochemical journal. 362(Pt 2) : 413-22, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11853550
  • Cerasi, E.Marshak, S.Totary, H.Melloul, D. [1997 Maurice Dérot. Transcriptional regulation of the insulin gene: a step toward gene therapy of diabetes]. Journées annuelles de diabétologie de l'Hôtel-Dieu. : 299-304, 1997. http://www.ncbi.nlm.nih.gov/pubmed/9296985
  • Marshak, S.Totary, H.Cerasi, E.Melloul, D. Purification of the beta-cell glucose-sensitive factor that transactivates the insulin gene differentially in normal and transformed islet cells. Proceedings of the National Academy of Sciences of the United States of America. 93(26) : 15057-62, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8986763

Positions Held

  • Associate Research Scientist (Physiology and Cellular Biophysics, Columbia University 2011 - 2013)
  • Postdoctoral Fellow (Physiology and Cellular Biophysics, Columbia University 2008 - 2011)

Awards/Honors

  • Robert W. Hobson, II, MD, Early Career Investigator Award (American Heart Association (The Council of Peripheral Vascular Disease) - 2013)
  • NIH Pathway to Independence Award (NIH/NHLBI - 2011)
  • NIH Postdoctoral Fellowship Award (NIH/NHLBI - 2008)
  • The Diabetes Research Centre of the Hebrew University (The Hebrew University of Jerusalem - 2004)
  • Israel Ministry of Science Fellowship Award (Israel Ministry of Science - 2003)
  • Israel Ministry of Science Fellowship Award (Israel Ministry of Science - 2002)